850176-30-6

Basic information

• Product Name: ADL5747
• Synonyms: ADL5747;N,N-diethyl-3-hydroxy-4-spiro[chromene-2,4'-piperidine]-4-ylbenzamide
• CAS NO: 850176-30-6
• Molecular Formula: C24H28N2O3
• Molecular Weight: 392.49072
• Mol File: 850176-30-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ADL5747(CAS DataBase Reference)
• NIST Chemistry Reference: ADL5747(850176-30-6)
• EPA Substance Registry System: ADL5747(850176-30-6)

Safety Data

• Hazardous Substances Data: 850176-30-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
ADL5747 is used as a cancer treatment agent for its ability to inhibit the activity of key kinases involved in the growth and proliferation of cancer cells. This inhibition may slow or stop the growth of cancer cells, offering a new approach to cancer therapy.
Used in Oncology Research:
In the field of oncology, ADL5747 is utilized as a research tool to study the role of kinases in cancer development and progression. Understanding the mechanisms by which ADL5747 interacts with these kinases can provide insights into the development of targeted cancer therapies.
Used in Drug Development:
ADL5747 serves as a lead compound in the development of new drugs targeting kinases in cancer treatment. Its potential to inhibit cancer cell growth makes it a valuable starting point for the design and synthesis of novel kinase inhibitors with improved efficacy and selectivity.
Used in Clinical Trials:
ADL5747 is employed in clinical trials to evaluate its safety, efficacy, and optimal dosing regimen in cancer patients. These trials are crucial for determining the potential of ADL5747 as a viable cancer treatment and for identifying any associated risks or side effects.

Upstream product

• 911228-78-9 tert-butyl 4-(4-(diethylcarbamoyl)-2-(methoxymethoxy)phenyl)spiro[chromene-2,4'-piperidine]-1'-carboxylate 

Relevant articles and documents

Spirocyclic delta opioid receptor agonists for the treatment of pain: Discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4′-piperidine]-4- yl) benzamide (ADL5747)

Selective, nonpeptidic δ opioid receptor agonists have been the subject of great interest as potential novel analgesic agents. The discoveries of BW373U86 (1) and SNC80 (2) contributed to the rapid expansion of research in this field. However, poor drug-like properties and low therapeutic indices have prevented clinical evaluation of these agents. Doses of 1 and 2 similar to those required for analgesic activity produce convulsions in rodents and nonhuman primates. Recently, we described a novel series of potent, selective, and orally bioavailable delta opioid receptor agonists. The lead derivative, ADL5859 (4), is currently in phase II proof-of-concept studies for the management of pain. Further structure activity relationship exploration has led to the discovery of ADL5747 (36), which is approximately 50-fold more potent than 4 in an animal model of inflammatory pain. On the basis of its favorable efficacy, safety, and pharmacokinetic profile, 36 was selected as a clinical candidate for the treatment of pain.

SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE

Spirocyclic heterocyclic derivatives, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the spirocyclic heterocyclic derivatives are ligands of the δ opioid receptor and may be useful, inter alia, for treating and/or preventing pain, anxiety, gastrointestinal disorders, and other δ opioid receptor-mediated conditions.

SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE

Spirocyclic heterocyclic derivatives, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the spirocyclic heterocyclic derivatives are ligands of the δ opioid receptor and